Aspira Women's Health Submits Request for Withdrawal of Form S-1 Registration Statement

Rhea-AI Summary

Aspira Women's Health (NASDAQ:AWH) has announced the withdrawal of its Form S-1 Registration Statement (No. 333-284182) with the Securities and Exchange Commission (SEC). The Registration Statement, initially filed on January 8, 2025, was intended for a public offering. The company confirmed that the Registration Statement was never declared effective by the SEC, and no securities were sold in connection with the proposed offering.

The company, which focuses on developing gynecologic disease diagnostic tools, has decided not to pursue the public offering at this time. This announcement does not constitute an offer to sell or solicitation to buy the company's common stock or other securities.

Positive

• None.

Negative

• Withdrawal of planned public offering indicates potential challenges in raising capital
• Cancellation of the S-1 registration may signal unfavorable market conditions or investor interest

Insights

Financial Analyst

The withdrawal of Aspira Women's Health's S-1 registration statement carries significant implications for the company's financial outlook and strategic positioning. This move, occurring merely five weeks after the initial filing, typically signals one of several scenarios: unfavorable market feedback during preliminary investor discussions, challenging market conditions for biotech offerings, or the emergence of more attractive financing alternatives.

The timing is particularly noteworthy as it comes during a period of heightened scrutiny in the biotech sector, where investors are increasingly selective about capital deployment. For existing shareholders, this development has mixed implications. While it temporarily removes the immediate dilution risk associated with a public offering, it also raises questions about how the company plans to fund its ongoing operations and development programs.

The biotech sector has seen a trend toward alternative financing structures in recent quarters, including private placements, royalty financing, and strategic partnerships. This withdrawal might indicate Aspira is pivoting toward one of these alternatives, which could potentially offer better terms or strategic advantages beyond mere capital raising.

For investors, the key focus should be on monitoring the company's next moves in securing necessary funding. The withdrawal doesn't eliminate the need for capital - it merely suggests a shift in strategy. This development underscores the importance of closely watching the company's cash position and burn rate in upcoming financial reports, as these metrics will become increasingly critical in assessing the company's financial sustainability.

AUSTIN, TX / ACCESS Newswire / February 13, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the "SEC") of the Company's Registration Statement on Form S-1 (No. 333-284182), as amended, originally filed on January 8, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company's common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such any state or jurisdiction.

About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.

OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery.

Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.

Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the SEC, including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investor Relations Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com

SOURCE: Aspira Women's Health

View the original press release on ACCESS Newswire

FAQ

Why did Aspira Women's Health (AWH) withdraw its S-1 Registration Statement in February 2025?

Aspira Women's Health withdrew its S-1 Registration Statement as the company decided not to pursue a public offering at this time. No specific reason was provided in the announcement.

When was AWH's withdrawn S-1 Registration Statement originally filed?

The S-1 Registration Statement (No. 333-284182) was originally filed on January 8, 2025.

Were any securities sold under AWH's withdrawn S-1 Registration?

No securities were sold in connection with the offering described in the Registration Statement, as it was never declared effective by the SEC.

What impact does the S-1 withdrawal have on AWH shareholders?

The withdrawal means AWH will not proceed with the planned public offering, which could affect the company's ability to raise capital through this particular avenue.